Network Activity
Activity period: 2020 – ongoing
National Funding:
“Medizinisch-Wissenschaftlicher Fonds des Bürgermeisters der Bundeshauptstadt Wien“
(Scientific Funds of the Major of Vienna) (2020-2021).
Description:
In March 2020, the World Health Organization declared the COVID-19 a global pandemic.
The collaborative outcomes study („Collaborative Outcomes study on
Health and Functioning during Infection Times (COH-FIT) -
Impact of the COVID-19 pandemic on physical and mental
well-being: a global survey”) is a large international survey project for the entire
population of countries affected by the coronavirus pandemic (COVID-19). Christoph Correll,
Berlin/Germany and New York/USA, and Marco Solmi, Padua/Italy, are the two COH-FIT project
leads, and Harald Aschauer leads the project in Vienna/Austria. The project involves almost
200 investigators in more than 35 countries and has been endorsed by multiple national and
international professional organizations. Both the COVID-19 pandemic and quarantine measures
can have marked detrimental effects on physical and mental health of the general population.
The objective of this study is to assess the impact of COVD-19 pandemic and related
quarantine measures on mental health of the general population. The hypothesis is that
the mental health of the general population is heavily affected by COVID-19, but that
risk and protective factors exist, which could inform strategies for mental health-care
after the pandemic is over, and inform also future preventive strategies, should other
pandemic situations arise. The survey will be distributed in three waves: wave 1 at the
current time of the COVID-19 pandemic (to compare the rating at the current time of COVID-19
with ratings recalled from before the time of the COVID-19), wave 2 after the COVID-19
pandemic has resolved (estimation: after 6 months, to compare ratings after the COVID-19
pandemic with ratings recalled during the time of the COVID-19 pandemic), and wave 3
(estimation: after 12 months, to compare long-term follow-up with the ratings recalled
from the acute and mid-term responses). For a subgroup of adult health care professionals,
additionally, a survey will be performed by a professional institute for field research.
The link to the survey: https://www.coh-fit.com
Participants:
Almost 200 researchers in more than 35 countries worldwide
Study period: 2017 – 2023
Sponsor:
Univ. Prof. René S. Kahn
Brain Center Rudolf Magnus
Department of Psychiatry
University Medical Center Utrecht, Netherlands
Subsidising Party:
Stanley Medical Research Institute
Sites at Universities, Hospitals and Institutes in
Austria, Germany, Israel, Italy, Norway, Spain, Switzerland, The Netherlands, United Kingdom
The chronic and severe mental disorder “psychosis” (e.g. schizophrenia) is usually preceded by a prodromal phase of attenuated psychotic symptoms and decline in function. During this prodromal state intervention could prevent transition to psychosis, and is of high significance.
The primary objective of this trial is to compare transition rates between individuals at ultra-high risk (UHR) for psychosis treated with omega-3 fatty acids to those randomised to placebo (treatment for six months and monitored in a 1.5 year clinical follow-up). The study is a multicentre, randomised, double-blind, placebo-controlled clinical trial and it aims to recruit 220 participants between the age of 13 and 20.
Secondary objectives of the trial include Magnetic Resonance Imaging (MRI), clinical symptomatology, social and cognitive function, quality of life and parameters identified by blood draw (e.g. bioactive lipids, genetic markers, immune parameters).
The project is approved in Austria by the local Ethics Committees and the Regulatory Authority (Austrian Federal Office for Safety in Health Care / BASG - Bundesamt für Sicherheit im Gesundheitswesen).
BioPsyC is the only site in Austria (Country Coordinator) and collaborates with e.g. University and specialized institutes.
Network Activity
Activity period: 2018 – 2022
Network funding:
COST – European Cooperation in Science and Technology
Avenue Louise 149
1050 Brussels
Belgium
www.cost.eu
Description:
„The Action Enhancing Psychiatric Genetic Counselling, Testing, and
Training in Europe (EnGagE) aims to strengthen pan-European research
into the newly emerging disciplines of Psychiatric Genetic Counselling
(PsyGC) and Psychiatric Genetic Testing (PsyGT); and to develop a
framework to facilitate the implementation of both disciplines into
routine clinical care.“ (Description at www.cost.eu)
Participants:
34 countries in Europe and Israel
Network Activity
Activity period: 2017 – 2021
Network funding:
COST – European Cooperation in Science and Technology
Avenue Louise 149
1050 Brussels
Belgium
www.cost.eu
Description:
„This Action focuses on patients with rare neurodevelopmental
disorders (NDD) whose study have the potential for major impact on
our understanding and treatment of NDD in general, including
schizophrenia and Autism Spectrum Disorder (ASD). NDD affect 1 in 25
individuals in Europe, and have high impact on healthcare systems,
economic development and society. Lack of mechanistic knowledge
hampers development of improved treatments. New knowledge from
psychiatric genomics provides for the first time a route to identify
neurobiological mechanisms underlying NDD. The key challenge is to
link genetic risk to altered brain biology.“ (Description at www.cost.eu)
Participants:
30 countries in Europe and Israel and 1 international partner
Aschauer Harald: Psychiatrische Erkrankungen plus Fallbeispiele. Vortrag: Österreichische Akademie der Ärzte, Fortbildungskurs Genetik 2013/2014, ÖÄK Diplomkurs. Hotel Strudlhof, 1090 Wien, 24.1.2014
Aschauer Harald: Genetik der Schizophrenie - Befunde, Möglichkeiten und Grenzen. Vortrag: Fortbildungsveranstaltung in der Landesnervenklinik OÖ Wagner – Jauregg Krankenhaus Linz, Psychiatrische Abteilung 1. Linz, 6.3.2014
Aschauer Harald: Aktueller Stand der Genetik schizophrener Störungen. Vortrag: Fortbildungsveranstaltung, Psychiatrische Abteilung, Donauspital, SMZ Ost der gemeinde Wien, Wien, 11.3.2014
Aschauer Harald: Genetik schizophrener Störungen und genetische Beratung. Vortrag: Fortbildungsveranstaltung der 4. Psychiatrischen Abteilung des Otto Wagner Spitals Wien, 7.10.2014
Aschauer Harald: Genetik schizophrener Störungen und genetische Beratung. Vortrag: Fortbildungsveranstaltung der 1. Psychiatrischen Abteilung des Otto Wagner Spitals Wien, 8.10.2015
Aschauer Harald: Genetik depressiver Erkrankungen. Vortrag: Seminar der ÖGPB – Akademie, Modul 43. Congress Center Messe Wien, 12.11.2015
Aschauer Harald: Psychiatrische Erkrankungen plus Fallbeispiele. Vortrag: Österreichische Akademie der Ärzte, Fortbildungskurs Genetik 2015/2016, ÖÄK Diplomkurs. Hotel Strudlhof, 1090 Wien, 22.1.2016
Aschauer Harald: Ist Nero ein Fall für den Psychiater? Vortrag: Rheinisches Landesmuseum Trier. Vortrag im Rahmen der Sonderausstellung “Nero – Kaiser, Künstler und Tyrann” (14.5.-16.10.2016), Trier, 22.9.2016
Aschauer Harald: Erhöhtes Risiko für Psychose – was ist zu tun? Vortrag: Landesklinikum Hollabrunn, Sozialpsychiatrie, Robert Löffler Straße 20, 2020 Hollabrunn, NÖ, Fortbildung, 18.5.2017
Aschauer Harald: Psychiatrische Erkrankungen plus Fallbeispiele. Vortrag: Österreichische Akademie der Ärzte, Fortbildungskurs Genetik 2017, ÖÄK Diplomkurs. Hotel Strudlhof, 1090 Wien, 10.6.2017
Aschauer Harald: Erhöhtes Risiko für Psychose – was ist zu tun? Vortrag: Sozialmedizinisches Zentrum Baumgartner Höhe Otto-Wagner-Spital und Pflegezentrum, 1. Psychiatrische Abteilung mit Zentrum für Psychotherapie und Psychosomatik, 1140 Wien, Fort- und Weiterbildung, 14.6.2018
Aschauer Harald: Psychiatrische Erkrankungen plus Fallbeispiele. Vortrag: Österreichische Akademie der Ärzte, Fortbildungskurs Genetik 2018/19, ÖÄK Diplomkurs. Hotel Strudlhof, 1090 Wien, 9.11.2018
Aschauer Harald: Psychiatrische Erkrankungen plus Fallbeispiele. Vortrag: Österreichische Akademie der Ärzte, Fortbildungskurs Genetik 2019/20, ÖÄK Diplomkurs. Hotel Strudlhof, 1090 Wien, 15.11.2019
Contact address:
Währinger Straße 18/2
1090 Vienna
Austria
Tel: +43-664-244 544 0
Email: office@biopsyc.at
Managing Director:
Harald Aschauer, MD, Assoc. Prof. ret. - CV
Email: harald.aschauer@biopsyc.at
Project team member:
Monika Schlögelhofer, MA
Email: monika.schloegelhofer@biopsyc.at
BioPsyC Biopsychosocial Corporation - Gemeinnützige Gesellschaft für Forschungsförderung GmbH (Non-profit Association for Research Funding Ltd.)
FN 426258a / HG Wien
Registered office:
Währinger Straße 18/2
1090 Vienna
Austria
Tel: +43-664-244 544 0
Email: office@biopsyc.at
www.biopsyc.at
The research and implementation of projects in the medical field and funding of such projects as a non-profit organization (not profit-oriented) and the cooperation with institutions of all kinds in the area of all medicine associated areas.